EP3052476
Setnir nikótínimíð hemlar BTK og framleiðsla þeirra og notkun við meðferð krabbameins, bólgu og sjálfnæmissjúkdóms
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
29.9.2014EP published:
15.7.2020EP application number:
14848083.3
EP translation filed:
9.9.2020Grant published:
15.10.2020EPO information:
European Patent Register
Max expiry date:
28.9.2034Expiry date:
28.9.2026Next due date:
30.9.2026
Title:
SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
Timeline
Today
29.9.2014EP application
15.7.2020EP Publication
9.9.2020Translation submitted
15.10.2020Registration published
28.9.2026Expires
Owner
Name:
Guangzhou InnoCare Pharma Tech Co., Ltd.Address:
Room 899 No. 333 Jiufo Jianshe Road, Sino-Singapore Guangzhou Knowledge City Guangzhou Guangdong 510130, CN
Inventor
Name:
CHEN, XiangyangAddress:
Changping District Beijing 102206, CN
Name:
GAO, YingxiangAddress:
Changping District Beijing 102206, CN
Name:
LIU, ChongAddress:
Shanghai 200131, CN
Name:
NI, HaihongAddress:
Shanghai 200131, CN
Name:
MULVIHILL, MarkAddress:
Waltham, MA 02453, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201361884958 PDate:
30.9.2013Country:
US
Number:
201310485048Date:
16.10.2013Country:
CN
Classification
Categories:
C07D 213/81, C07D 213/84, C07D 231/36, C07D 277/56, C07D 263/34, C07D 401/14, C07D 401/04, C07D 401/12, C07C 233/65, A61K 31/4418, A61K 31/4427, A61K 31/415, A61K 31/4155, A61K 31/426, A61K 31/421, A61K 31/4468, A61K 31/166, A61P 35/00, C07D 239/47, A61K 31/505
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 22.9.2020
Expires: 28.9.2021
Payer: Patice ehf.
Number: 8
Paid: 21.9.2021
Expires: 28.9.2022
Payer: Árnason Faktor ehf.
Number: 9
Paid: 27.9.2022
Expires: 28.9.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 28.9.2023
Expires: 28.9.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 19.8.2024
Expires: 28.9.2025
Payer: Acumass
Number: 12
Paid: 20.8.2025
Expires: 28.9.2026
Payer: Acumass